LY3499446 (KRASG12C IN-13) is a potent inhibitor of KRAS G12C. It can be used in research on advanced solid tumors, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

YDR1 is a potent, selective and orally bioavailable Cereblon-based PROTAC and a degrader of SMARCA2 with DC50 of 60 nM at 48 hours. It exhibits antitumor activity in SMARCA4-mutant lung cancer xenograft models and can be used in research on non-small cell lung cancer.

YD54 is a potent, selective and orally bioavailable PROTAC and a degrader of SMARCA2 with DC50 of 8.1 nM at 24 hours. It exhibits antitumor activity in SMARCA4-mutant lung cancer xenograft models and can be used in research on non-small cell lung cancer.

ABD0171 is a potent, irreversible, and selective inhibitor of aldehyde dehydrogenase 1A3 (ALDH1A3), with an IC50 of 0.34 µM using the physiological substrate all-trans-retinaldehyde (atRAL). It also inhibits ALDH1A2 and ALDH1A1 with IC50 of 0.79 µM and 6.6 µM, respectively. ABD0171 disrupts key oncogenic pathways in triple-negative breast cancer (TNBC) cells in vitro and exhibits robust antitumor and […]

GEM144 is a potent and orally active dual inhibitor of DNA polymerase α (POLA1) and HDAC11 . It exhibits potent antiproliferative activity in vitro and antitumor efficacy in vivo by inducing p53 acetylation, p21 activation, G1/S cell cycle arrest, and apoptosis.

dTAGV-1 TFA is a potent and selective degrader that recruits the VHL E3 ligase to selectively degrade FKBP12F36V-tagged proteins. It enables rapid degradation of oncogenic proteins such as KRASG12V and EWS/FLI, demonstrating significant antitumor efficacy both in vitro and in vivo.

Flezurafenib is an oral inhibitor of pan-RAF with potential antineoplastic activity.

YW-N-7 TFA is a PROTAC that targets the inhibition and degradation of RET with a DC50 of 88 nM. It also exhibits antitumor activity in a KIF5B-RET-driven xenograft mouse model.

Ivospemin is a spermine analogue and polyamine inhibitor that lowers polyamine levels by inhibiting the activity of the polyamine biosynthetic enzyme ornithine decarboxylase (ODC) in cancer cell lines. It shows potential as a treatment for metastatic pancreatic adenocarcinoma.

YX0597 is a potent and selective CDK9 PROTAC degrader that reduces RNA polymerase II S2 phosphorylation and MCL1 expression in GA0518 and AGS cells. It effectively inhibits GEAC cell growth, including radiation-resistant tumors, and suppresses tumor proliferation, metastasis, and cancer stem cells.